PluriPLUR +1.19%25 Gross Margin % is 33.53% as of Mar. 2026, which is 65% below its 10-year median of 96.40. GuruFocus rates PLUR with a GF Score™ of 25/100 and a GF Value™ of $6.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 738 Biotechnology companies, Pluri ranks worse than 66.67% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Pluri's Gross Profit for the
three
months ended in Mar. 2026 was $0.06 Mil. Pluri's Revenue for the
three
months ended in Mar. 2026 was $0.17 Mil. Therefore, Pluri's Gross Margin % for the quarter that ended in Mar. 2026 was 33.53%.
The historical rank and industry rank for Pluri's Gross Margin % or its related term are showing as below:
PLUR'
s Gross Margin % Range Over the Past 10 Years
Min: 43 Med: 96.4 Max: 98.77
Current: 43
During the past 13 years, the highestGross Margin % of Pluri was 98.77%. The lowest was 43.00%. And the median was 96.40%.
PLUR's Gross Margin % is ranked worse than 66.67% of 738
companies
in the Biotechnology industry
Industry Median: 60.94
vs PLUR: 43.00
Pluri had a gross margin of 33.53% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Pluri was 0.00% per year.
Pluri (NAS:PLUR) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Pluri had a gross margin of 33.53% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Pluri Gross Margin % Related Terms
Pluri Gross Margin % Historical Data
* Premium members only.
The historical data trend for Pluri's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLUR vs VTGN, PTN, CLRB: Gross Margin % Comparison
For the Biotechnology subindustry, Pluri's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pluri Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pluri's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Pluri's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Pluri (PLUR) has a Gross Margin % of 33.53% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Pluri and its competitors. This is 65% below median its historical median of 96.40. Over the past decade, Pluri's Gross Margin % has ranged from 43.00 to 98.77. According to the industry distribution chart, Pluri ranks #492 out of 738 companies in the Biotechnology industry, placing it in the top 66.7%.
Is Pluri's Gross Margin % too high?
Pluri's current Gross Margin % of 33.53% is 65% below median its 10-year median of 96.40. Over the past 10 years, this metric has ranged from a low of 43.00 to a high of 98.77. The Biotechnology industry median Gross Margin % is 60.94. Pluri's value of 33.53% is 45% below this industry median. Based on the distribution chart, Pluri ranks #492 out of 738 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pluri has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pluri's Gross Margin % compare to VTGN and PTN?
According to the Biotechnology industry distribution chart, Pluri ranks #492 out of 738 companies for Gross Margin %. This places Pluri in the lower half of its industry. The industry median Gross Margin % is 60.94. Pluri's value of 33.53% is 45% below this benchmark. Historically, Pluri's own Gross Margin % has ranged from 43.00 to 98.77 over the past decade. While the company's 10-year median is 96.40 vs. the industry median of 60.94, Pluri has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pluri's current Gross Margin % of 33.53% is 45% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Pluri and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pluri's current Gross Margin % is 33.53%, which is 65% below median its own 10-year median of 96.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Based on GuruFocus' analysis, Pluri (PLUR) is currently considered Possible Value Trap. The stock's GF Value™ is $6.46, compared to a current price of $2.12 — trading 67.2% below its estimated fair value. The current Gross Margin % is 33.53%, which is 65% below median its 10-year median of 96.40 and 45% below the Biotechnology industry median of 60.94. Pluri's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Pluri (PLUR), the current Gross Margin % is 33.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pluri (PLUR) Overvalued in 2026?
Based on GuruFocus' analysis, Pluri stock appears to be undervalued.
The current stock price of $2.12 is trading 67.2% below its estimated GF Value™ of $6.46.
GuruFocus considers Pluri to be Possible Value Trap.
Key valuation signals for PLUR:
Gross Margin %: 33.53% (65% below median its 10-year median of 96.40)
GF Value™: $6.46 vs. price of $2.12 (67.2% below fair value)
Industry Position: 45% below the Biotechnology median (#492 of 738)
No single metric tells the full story. See the PLUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score
Get the complete analysis for PLUR
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLUR has been successfully added to your 
